FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1052-1056 April 5, 2001 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Gastrointestinal stromal tumors are a group of mesenchymal neoplasms that arise from precursors of the connective-tissue cells of the gastrointestinal tract.¹ They occur predominantly in middle-aged and older persons, and approximately 70 percent of the tumors are found in the stomach, 20 to 30 percent are found in the small intestine, and less than 10 percent are found elsewhere in the gastrointestinal tract.¹ Recent studies have shown that cells in gastrointestinal stromal tumors express a growth factor receptor with tyrosine kinase activity termed c-kit. This receptor, the product of the proto-oncogene c-kit, can be detected by immunohistochemical staining for . . . [Full Text of this Article]

Case Report

Methods

Results

Evaluation of the Response by MRI

Evaluation by PET Scanning with [¹⁸F]Fluorodeoxyglucose

Histologic Findings

Side Effects of STI571

Discussion

Source Information

From the Departments of Oncology (H.J.) and Radiology (P.T.), Helsinki University Central Hospital, Helsinki, Finland; the Department of Surgery, Turku University Central Hospital, Turku, Finland (P.J.R.); the Department of Pathology, Haartman Institute, University of Helsinki, Helsinki (M.S.-R., L.C.A.); the Department of Biology and Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge (D.T.); the Center for Sarcoma and Bone Oncology, Department of Adult Oncology, Dana–Farber Cancer Institute and Harvard Medical School, Boston (D.T., G.D.D.); Novartis Oncology, East Hanover, N.J. (S.S.), and Basel, Switzerland (R.C., S.D.); and the Department of Medical Oncology, Oregon Health Sciences University, Portland (B.D.). Drs. Joensuu and Roberts contributed equally to the article.

Address reprint requests to Dr. Joensuu at the Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, P.O. Box 180, FIN-00029, Helsinki, Finland.

References

This article has been cited by other articles:

• Yamaguchi, U., Nakayama, R., Honda, K., Ichikawa, H., Hasegawa, T., Shitashige, M., Ono, M., Shoji, A., Sakuma, T., Kuwabara, H., Shimada, Y., Sasako, M., Shimoda, T., Kawai, A., Hirohashi, S., Yamada, T. (2008). Distinct Gene Expression-Defined Classes of Gastrointestinal Stromal Tumor. JCO 26: 4100-4108 [Abstract] [Full Text]  
• Mabasa, V. H, Taylor, S. C., Chu, C. C., Moravan, V., Johnston, K., Peacock, S., Knowling, M. (2008). Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). J Oncol Pharm Pract 14: 105-112 [Abstract]  
• Mussi, C., Schildhaus, H.-U., Gronchi, A., Wardelmann, E., Hohenberger, P. (2008). Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1. Clin. Cancer Res. 14: 4550-4555 [Abstract] [Full Text]  
• Montero, J. C., Lopez-Perez, R., San Miguel, J. F., Pandiella, A. (2008). Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. haematol 93: 851-859 [Abstract] [Full Text]  
• Gioni, V., Karampinas, T., Voutsinas, G., Roussidis, A. E., Papadopoulos, S., Karamanos, N. K., Kletsas, D. (2008). Imatinib Mesylate Inhibits Proliferation and Exerts an Antifibrotic Effect in Human Breast Stroma Fibroblasts. Mol Cancer Res 6: 706-714 [Abstract] [Full Text]  
• Tabone-Eglinger, S., Subra, F., El Sayadi, H., Alberti, L., Tabone, E., Michot, J.-P., Theou-Anton, N., Lemoine, A., Blay, J.-Y., Emile, J.-F. (2008). KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors. Clin. Cancer Res. 14: 2285-2294 [Abstract] [Full Text]  
• Van den Abbeele, A. D. (2008). The Lessons of GIST--PET and PET/CT: A New Paradigm for Imaging. The Oncologist 13: 8-13 [Abstract] [Full Text]  
• Judson, I. R. (2008). Imatinib for Patients With Liver or Kidney Dysfunction: No Need to Modify the Dose. JCO 26: 521-522 [Full Text]  
• Gibbons, J., Egorin, M. J., Ramanathan, R. K., Fu, P., Mulkerin, D. L., Shibata, S., Takimoto, C. H.M., Mani, S., LoRusso, P. A., Grem, J. L., Pavlick, A., Lenz, H.-J., Flick, S. M., Reynolds, S., Lagattuta, T. F., Parise, R. A., Wang, Y., Murgo, A. J., Ivy, S. P., Remick, S. C. (2008). Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. JCO 26: 570-576 [Abstract] [Full Text]  
• Blanke, C. D., Demetri, G. D., von Mehren, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., Corless, C. L., Fletcher, C. D.M., Roberts, P. J., Heinz, D., Wehre, E., Nikolova, Z., Joensuu, H. (2008). Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. JCO 26: 620-625 [Abstract] [Full Text]  
• Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H.C., Baker, L. H., Maki, R. G., Tanaka, M., Hecht, J. R., Heinrich, M. C., Fletcher, C. D.M., Crowley, J. J., Borden, E. C. (2008). Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. JCO 26: 626-632 [Abstract] [Full Text]  
• Joensuu, H., De Braud, F., Coco, P., De Pas, T., Putzu, C., Spreafico, C., Bono, P., Bosselli, S., Jalava, T., Laurent, D., Casali, P. G. (2008). Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 19: 173-177 [Abstract] [Full Text]  
• Boss, D. S., Olmos, R. V., Sinaasappel, M., Beijnen, J. H., Schellens, J. H. M. (2008). Application of PET/CT in the Development of Novel Anticancer Drugs. The Oncologist 13: 25-38 [Abstract] [Full Text]  
• Holdsworth, C. H., Badawi, R. D., Manola, J. B., Kijewski, M. F., Israel, D. A., Demetri, G. D., Van den Abbeele, A. D. (2007). CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor. Am. J. Roentgenol. 189: W324-W330 [Abstract] [Full Text]  
• Jones, C., Rodriguez-Pinilla, M., Lambros, M., Bax, D., Messahel, B., Vujanic, G. M, Reis-Filho, J. S, Pritchard-Jones, K. (2007). c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J. Clin. Pathol. 60: 1226-1231 [Abstract] [Full Text]  
• Armbrust, T, Sobotta, M, Ramadori, G (2007). Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib. Ann Oncol 18: 1123-1125 [Full Text]  
• Sleijfer, S., Wiemer, E., Seynaeve, C., Verweij, J. (2007). Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment. The Oncologist 12: 719-726 [Abstract] [Full Text]  
• Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., Benjamin, R. S. (2007). Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. JCO 25: 1753-1759 [Abstract] [Full Text]  
• Pollack, I. F., Jakacki, R. I., Blaney, S. M., Hancock, M. L., Kieran, M. W., Phillips, P., Kun, L. E., Friedman, H., Packer, R., Banerjee, A., Geyer, J. R., Goldman, S., Poussaint, T. Y., Krasin, M. J., Wang, Y., Hayes, M., Murgo, A., Weiner, S., Boyett, J. M. (2007). Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol 9: 145-160 [Abstract] [Full Text]  
• Jamali, F. R., Darwiche, S. S., El-Kinge, N., Tawil, A., Soweid, A. M. (2007). Disease Progression Following Imatinib Failure in Gastrointestinal Stromal Tumors: Role of Surgical Therapy. The Oncologist 12: 438-442 [Abstract] [Full Text]  
• Blay, J.-Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., Cupissol, D., Guillemet, C., Kerbrat, P., Fayette, J., Chabaud, S., Berthaud, P., Perol, D. (2007). Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. JCO 25: 1107-1113 [Abstract] [Full Text]  
• Yeh, C.-N., Chen, T.-W., Lee, H.-L., Liu, Y.-Y., Chao, T.-C., Hwang, T.-L., Jan, Y.-Y., Chen, M.-F. (2007). Kinase Mutations and Imatinib Mesylate Response for 64 Taiwanese with Advanced GIST: Preliminary Experience from Chang Gung Memorial Hospital. Ann. Surg. Oncol. 14: 1123-1128 [Abstract] [Full Text]  
• Bozulic, L., Morin, P. J., Hunter, T., Hemmings, B. A. (2007). Meeting Report: Targeting the Kinome--20 Years of Tyrosine Kinase Inhibitor Research in Basel. Sci Signal 2007: pe8-pe8 [Abstract] [Full Text]  
• Haller, F., Detken, S., Schulten, H.-J., Happel, N., Gunawan, B., Kuhlgatz, J., Fuzesi, L. (2007). Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations. Ann. Surg. Oncol. 14: 526-532 [Abstract] [Full Text]  
• Wu, Y., Zhu, X., Ding, Y. (2007). Diagnosis and Treatment of Gastrointestinal Stromal Tumors of the Stomach: Report of 28 Cases.. Annals of Clinical & Laboratory Science 37: 15-21 [Abstract] [Full Text]  
• Gold, J. S., van der Zwan, S. M., Gonen, M., Maki, R. G., Singer, S., Brennan, M. F., Antonescu, C. R., De Matteo, R. P. (2007). Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. Ann. Surg. Oncol. 14: 134-142 [Abstract] [Full Text]  
• Stewart, D. R, Corless, C. L, Rubin, B. P, Heinrich, M. C, Messiaen, L. M, Kessler, L. J, Zhang, P. J, Brooks, D. G (2007). Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1. J. Med. Genet. 44: e61-e61 [Abstract] [Full Text]  
• Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., Cortes, J. (2006). New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. ANN INTERN MED 145: 913-923 [Abstract] [Full Text]  
• Lassau, N., Lamuraglia, M., Chami, L., Leclere, J., Bonvalot, S., Terrier, P., Roche, A., Le Cesne, A. (2006). Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography.. Am. J. Roentgenol. 187: 1267-1273 [Abstract] [Full Text]  
• Delbaldo, C., Chatelut, E., Re, M., Deroussent, A., Seronie-Vivien, S., Jambu, A., Berthaud, P., Le Cesne, A., Blay, J.-Y., Vassal, G. (2006). Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors.. Clin. Cancer Res. 12: 6073-6078 [Abstract] [Full Text]  
• (2006). Image of the month--answer.. Arch Surg 141: 1044-1044 [Full Text]  
• Meza-Zepeda, L. A., Kresse, S. H., Barragan-Polania, A. H., Bjerkehagen, B., Ohnstad, H. O., Namlos, H. M., Wang, J., Kristiansen, B. E., Myklebost, O. (2006). Array Comparative Genomic Hybridization Reveals Distinct DNA Copy Number Differences between Gastrointestinal Stromal Tumors and Leiomyosarcomas.. Cancer Res. 66: 8984-8993 [Abstract] [Full Text]  
• Matsukuma, S., Yoshihara, M., Kasai, F., Kato, A., Yoshida, A., Akaike, M., Kobayashi, O., Nakayama, H., Sakuma, Y., Yoshida, T., Kameda, Y., Tsuchiya, E., Miyagi, Y. (2006). Rapid and Simple Detection of Hot Spot Point Mutations of Epidermal Growth Factor Receptor, BRAF, and NRAS in Cancers Using the Loop-Hybrid Mobility Shift Assay. J. Mol. Diagn. 8: 504-512 [Abstract] [Full Text]  
• Linton, K M, Taylor, M B, Radford, J A (2006). Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br. J. Radiol. 79: e40-e44 [Abstract] [Full Text]  
• Gabillot-Carre, M., Lepelletier, Y., Humbert, M., de Sepuvelda, P., Hamouda, N. B., Zappulla, J. P., Liblau, R., Ribadeau-Dumas, A., Machavoine, F., Letard, S., Baude, C., Hermant, A., Yang, Y., Vargaftig, J., Bodemer, C., Morelon, E., Lortholary, O., Recher, C., Laurent, G., Dy, M., Arock, M., Dubreuil, P., Hermine, O. (2006). Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108: 1065-1072 [Abstract] [Full Text]  
• Tornillo, L, Terracciano, L M (2006). An update on molecular genetics of gastrointestinal stromal tumours.. J. Clin. Pathol. 59: 557-563 [Abstract] [Full Text]  
• Kersting, C, Packeisen, J, Leidinger, B, Brandt, B, von Wasielewski, R, Winkelmann, W, van Diest, P J, Gosheger, G, Buerger, H (2006). Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J. Clin. Pathol. 59: 585-590 [Abstract] [Full Text]  
• Tarn, C., Skorobogatko, Y. V., Taguchi, T., Eisenberg, B., von Mehren, M., Godwin, A. K. (2006). Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms.. Cancer Res. 66: 5477-5486 [Abstract] [Full Text]  
• Hahn, S. M., Fraker, D. L., Mick, R., Metz, J., Busch, T. M., Smith, D., Zhu, T., Rodriguez, C., Dimofte, A., Spitz, F., Putt, M., Rubin, S. C., Menon, C., Wang, H.-W., Shin, D., Yodh, A., Glatstein, E. (2006). A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and Sarcomatosis. Clin. Cancer Res. 12: 2517-2525 [Abstract] [Full Text]  
• Thomson, J., Schofield, P., Mileshkin, L., Agalianos, E., Savulescu, J., Zalcberg, J., Jefford, M. (2006). Do oncologists discuss expensive anti-cancer drugs with their patients?. Ann Oncol 17: 702-708 [Abstract] [Full Text]  
• Hong, X., Choi, H., Loyer, E. M., Benjamin, R. S., Trent, J. C., Charnsangavej, C. (2006). Gastrointestinal Stromal Tumor: Role of CT in Diagnosis and in Response Evaluation and Surveillance after Treatment with Imatinib.. RadioGraphics 26: 481-495 [Abstract] [Full Text]  
• Warakaulle, D. R., Gleeson, F. (2006). MDCT Appearance of Gastrointestinal Stromal Tumors After Therapy with Imatinib Mesylate. Am. J. Roentgenol. 186: 510-515 [Abstract] [Full Text]  
• von Schulthess, G. K., Steinert, H. C., Hany, T. F. (2006). Integrated PET/CT: Current Applications and Future Directions. Radiology 238: 405-422 [Abstract] [Full Text]  
• Rao, A. S., Kremenevskaja, N., von Wasielewski, R., Jakubcakova, V., Kant, S., Resch, J., Brabant, G. (2006). Wnt/{beta}-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer. J. Clin. Endocrinol. Metab. 91: 159-168 [Abstract] [Full Text]  
• Kondo, S., Yamaguchi, U., Sakurai, S., Ikezawa, Y., Chuman, H., Tateishi, U., Furuta, K., Hasegawa, T. (2005). Cytogenetic Confirmation of a Gastrointestinal Stromal Tumor and Ewing Sarcoma/Primitive Neuroectodermal Tumor in a Single Patient. Jpn J Clin Oncol 35: 753-756 [Abstract] [Full Text]  
• McLean, S. R., Gana-Weisz, M., Hartzoulakis, B., Frow, R., Whelan, J., Selwood, D., Boshoff, C. (2005). Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Molecular Cancer Therapeutics 4: 2008-2015 [Abstract] [Full Text]  
• Scher, H. I., Sawyers, C. L. (2005). Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. JCO 23: 8253-8261 [Abstract] [Full Text]  
• Jefford, M., Savulescu, J., Thomson, J., Schofield, P., Mileshkin, L., Agalianos, E., Zalcberg, J. (2005). Medical paternalism and expensive unsubsidised drugs. BMJ 331: 1075-1077 [Full Text]  
• Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., Krebs, A. D., Johnson, D. H., Giaccone, G., Herbst, R. S., Manegold, C., Fukuoka, M., Kris, M. G., Baselga, J., Ochs, J. S., Haber, D. A. (2005). Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. JCO 23: 8081-8092 [Abstract] [Full Text]  
• Theou, N., Gil, S., Devocelle, A., Julie, C., Lavergne-Slove, A., Beauchet, A., Callard, P., Farinotti, R., Le Cesne, A., Lemoine, A., Faivre-Bonhomme, L., Emile, J.-F. (2005). Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib. Clin. Cancer Res. 11: 7593-7598 [Abstract] [Full Text]  
• Sleijfer, S., Seynaeve, C., Verweij, J. (2005). Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care. The Oncologist 10: 833-841 [Abstract] [Full Text]  
• Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., Meltzer, P. S. (2005). Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma Biology. Cancer Res. 65: 9226-9235 [Abstract] [Full Text]  
• Martin, J., Poveda, A., Llombart-Bosch, A., Ramos, R., Lopez-Guerrero, J. A., del Muro, J. G., Maurel, J., Calabuig, S., Gutierrez, A., de Sande, J. L. G., Martinez, J., De Juan, A., Lainez, N., Losa, F., Alija, V., Escudero, P., Casado, A., Garcia, P., Blanco, R., Buesa, J. M. (2005). Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). JCO 23: 6190-6198 [Abstract] [Full Text]  
• Rossi, G, Sartori, G, Valli, R, Bertolini, F, Bigiani, N, Schirosi, L, Cavazza, A, Luppi, G (2005). The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour. J. Clin. Pathol. 58: 991-993 [Abstract] [Full Text]  
• Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H. III, Edeen, P. T., Floyd, M., Ford, J. M., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Mehta, S. A., Patel, H. K., Pao, W., Sawyers, C. L., Varmus, H., Zarrinkar, P. P., Lockhart, D. J. (2005). Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102: 11011-11016 [Abstract] [Full Text]  
• Rubin, B. P., Antonescu, C. R., Scott-Browne, J. P., Comstock, M. L., Gu, Y., Tanas, M. R., Ware, C. B., Woodell, J. (2005). A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E. Cancer Res. 65: 6631-6639 [Abstract] [Full Text]  
• Petti, F., Thelemann, A., Kahler, J., McCormack, S., Castaldo, L., Hunt, T., Nuwaysir, L., Zeiske, L., Haack, H., Sullivan, L., Garton, A., Haley, J. D. (2005). Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930. Molecular Cancer Therapeutics 4: 1186-1197 [Abstract] [Full Text]  
• Juurikivi, A, Sandler, C, Lindstedt, K A, Kovanen, P T, Juutilainen, T, Leskinen, M J, Maki, T, Eklund, K K (2005). Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 64: 1126-1131 [Abstract] [Full Text]  
• Korja, M, Finne, J, Salmi, T T, Haapasalo, H, Tanner, M, Isola, J (2005). No GIST-type c-kit gain of function mutations in neuroblastic tumours. J. Clin. Pathol. 58: 762-765 [Abstract] [Full Text]  
• Loughrey, M B, Mitchell, C, Mann, G B, Michael, M, Waring, P M (2005). Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J. Clin. Pathol. 58: 779-781 [Abstract] [Full Text]  
• Nunobe, S., Sano, T., Shimada, K., Sakamoto, Y., Kosuge, T. (2005). Surgery Including Liver Resection for Metastatic Gastrointestinal Stromal Tumors or Gastrointestinal Leiomyosarcomas. Jpn J Clin Oncol 35: 338-341 [Abstract] [Full Text]  
• Antonescu, C. R., Besmer, P., Guo, T., Arkun, K., Hom, G., Koryotowski, B., Leversha, M. A., Jeffrey, P. D., Desantis, D., Singer, S., Brennan, M. F., Maki, R. G., DeMatteo, R. P. (2005). Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clin. Cancer Res. 11: 4182-4190 [Abstract] [Full Text]  
• Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., Fukui, H. (2005). Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G907-G913 [Abstract] [Full Text]  
• Li, F. P., Fletcher, J. A., Heinrich, M. C., Garber, J. E., Sallan, S. E., Curiel-Lewandrowski, C., Duensing, A., van de Rijn, M., Schnipper, L. E., Demetri, G. D. (2005). Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred. JCO 23: 2735-2743 [Abstract] [Full Text]  
• Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., Shankar, L., Larson, S. M., Sigman, C. C., Schilsky, R. L., Sullivan, D. C. (2005). Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. Clin. Cancer Res. 11: 2785-2808 [Abstract] [Full Text]  
• Blay, J.-Y., Bonvalot, S., Casali, P., Choi, H., Debiec-Richter, M., Dei Tos, A. P., Emile, J.-F., Gronchi, A., Hogendoorn, P. C. W., Joensuu, H., Le Cesne, A., Mac Clure, J., Maurel, J., Nupponen, N., Ray-Coquard, I., Reichardt, P., Sciot, R., Stroobants, S., van Glabbeke, M., van Oosterom, A., Demetri, G. D., On behalf of the GIST consensus meeting panelists, (2005). Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16: 566-578 [Abstract] [Full Text]  
• Tanaka, A., Konno, M., Muto, S., Kambe, N., Morii, E., Nakahata, T., Itai, A., Matsuda, H. (2005). A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324-2331 [Abstract] [Full Text]  
• De Giorgi, U., Verweij, J. (2005). Imatinib and gastrointestinal stromal tumors: Where do we go from here?. Molecular Cancer Therapeutics 4: 495-501 [Abstract] [Full Text]  
• Busalacchi, P. J. B. Sr., de la Calle, M. A. C., Torroba, A., del Rio, S. T. (2005). Gastrointestinal Stromal Tumor with Metastases in an Adult Woman Treated with Imatinib Mesylate: MDCT Findings. Am. J. Roentgenol. 184: S58-S61 [Full Text]  
• Sihto, H., Sarlomo-Rikala, M., Tynninen, O., Tanner, M., Andersson, L. C., Franssila, K., Nupponen, N. N., Joensuu, H. (2005). KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors. JCO 23: 49-57 [Abstract] [Full Text]  
• Lennartsson, J., Jelacic, T., Linnekin, D., Shivakrupa, R. (2005). Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit. Stem Cells 23: 16-43 [Abstract] [Full Text]  
• Uccini, S., Mannarino, O., McDowell, H. P., Pauser, U., Vitali, R., Natali, P. G., Altavista, P., Andreano, T., Coco, S., Boldrini, R., Bosco, S., Clerico, A., Cozzi, D., Donfrancesco, A., Inserra, A., Kokai, G., Losty, P. D., Nicotra, M. R., Raschella, G., Tonini, G. P., Dominici, C. (2005). Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors. Clin. Cancer Res. 11: 380-389 [Abstract] [Full Text]  
• Choi, H., Charnsangavej, C., Faria, S. d. C., Tamm, E. P., Benjamin, R. S., Johnson, M. M., Macapinlac, H. A., Podoloff, D. A. (2004). CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings. Am. J. Roentgenol. 183: 1619-1628 [Abstract] [Full Text]  
• Went, P. Th., Dirnhofer, S., Bundi, M., Mirlacher, M., Schraml, P., Mangialaio, S., Dimitrijevic, S., Kononen, J., Lugli, A., Simon, R., Sauter, G. (2004). Prevalence of KIT Expression in Human Tumors. JCO 22: 4514-4522 [Abstract] [Full Text]  
• Fagin, J A (2004). How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183: 249-256 [Abstract] [Full Text]  
• Demetri, G. D., Titton, R. L., Ryan, D. P., Fletcher, C. D.M. (2004). Case 32-2004 - A 68-Year-Old Man with a Large Retroperitoneal Mass. NEJM 351: 1779-1787 [Full Text]  
• O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A. III, Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Shakespeare, W. C., Dalgarno, D., Clackson, T., Sawyer, T. K., Deininger, M. W., Druker, B. J. (2004). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104: 2532-2539 [Abstract] [Full Text]  
• Corless, C. L., Fletcher, J. A., Heinrich, M. C. (2004). Biology of Gastrointestinal Stromal Tumors. JCO 22: 3813-3825 [Abstract] [Full Text]  
• Heymach, J. V., Desai, J., Manola, J., Davis, D. W., McConkey, D. J., Harmon, D., Ryan, D. P., Goss, G., Quigley, T., Van den Abbeele, A. D., Silverman, S. G., Connors, S., Folkman, J., Fletcher, C. D. M., Demetri, G. D. (2004). Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas. Clin. Cancer Res. 10: 5732-5740 [Abstract] [Full Text]  
• Dietz, A. B., Souan, L., Knutson, G. J., Bulur, P. A., Litzow, M. R., Vuk-Pavlovic, S. (2004). Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099 [Abstract] [Full Text]  
• West, R. B., Corless, C. L., Chen, X., Rubin, B. P., Subramanian, S., Montgomery, K., Zhu, S., Ball, C. A., Nielsen, T. O., Patel, R., Goldblum, J. R., Brown, P. O., Heinrich, M. C., van de Rijn, M. (2004). The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status. Am. J. Pathol. 165: 107-113 [Abstract] [Full Text]  
• Tang, X, Boxer, M, Drummond, A, Ogston, P, Hodgins, M, Burden, A D (2004). A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J. Med. Genet. 41: e88-e88 [Full Text]  
• Ozvegy-Laczka, C., Heged""s, T., Varady, G., Ujhelly, O., Schuetz, J. D., Varadi, A., Keri, G., Orfi, L., Nemet, K., Sarkadi, B. (2004). High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter. Mol. Pharmacol. 65: 1485-1495 [Abstract] [Full Text]  
• Raspollini, M. R., Amunni, G., Villanucci, A., Pinzani, P., Simi, L., Paglierani, M., Taddei, G. L. (2004). c-Kit Expression in Patients with Uterine Leiomyosarcomas: A Potential Alternative Therapeutic Treatment. Clin. Cancer Res. 10: 3500-3503 [Abstract] [Full Text]  
• Wolff, N. C., Randle, D. E., Egorin, M. J., Minna, J. D., Ilaria, R. L. Jr. (2004). Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer. Clin. Cancer Res. 10: 3528-3534 [Abstract] [Full Text]  
• Eisenberg, B. L., Judson, I. (2004). Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann. Surg. Oncol. 11: 465-475 [Abstract] [Full Text]  
• Dziba, J. M., Ain, K. B. (2004). Imatinib Mesylate (Gleevec; STI571) Monotherapy Is Ineffective in Suppressing Human Anaplastic Thyroid Carcinoma Cell Growth in Vitro. J. Clin. Endocrinol. Metab. 89: 2127-2135 [Abstract] [Full Text]  
• Bono, P., Krause, A., von Mehren, M., Heinrich, M. C., Blanke, C. D., Dimitrijevic, S., Demetri, G. D., Joensuu, H. (2004). Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103: 2929-2935 [Abstract] [Full Text]  
• Stefanou, D., Batistatou, A., Zioga, A., Arkoumani, E., Papachristou, D. J., Agnantis, N. J. (2004). Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) and C-KIT in Cutaneous Melanocytic Lesions. INT J SURG PATHOL 12: 133-138 [Abstract]  
• Raspollini, M. R., Amunni, G., Villanucci, A., Baroni, G., Taddei, A., Taddei, G. L. (2004). c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol 15: 594-597 [Abstract] [Full Text]  
• Neville, K., Parise, R. A., Thompson, P., Aleksic, A., Egorin, M. J., Balis, F. M., McGuffey, L., McCully, C., Berg, S. L., Blaney, S. M. (2004). Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates. Clin. Cancer Res. 10: 2525-2529 [Abstract] [Full Text]  
• Kaelin, W. G. Jr. (2004). Gleevec: Prototype or Outlier?. Sci Signal 2004: pe12-pe12 [Abstract] [Full Text]  
• Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., Neel, B. G. (2004). Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101: 3130-3135 [Abstract] [Full Text]  
• Burman, K. D. (2004). A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting. Endocrinology 145: 1027-1030 [Full Text]  
• Antoch, G., Kanja, J., Bauer, S., Kuehl, H., Renzing-Koehler, K., Schuette, J., Bockisch, A., Debatin, J. F., Freudenberg, L. S. (2004). Comparison of PET, CT, and Dual-Modality PET/CT Imaging for Monitoring of Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors. JNM 45: 357-365 [Abstract] [Full Text]  
• Reichardt, P, Schneider, U, Stroszczynski, C, Pink, D, Hohenberger, P (2004). Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J. Clin. Pathol. 57: 215-217 [Abstract] [Full Text]  
• Apte, S. M., Fan, D., Killion, J. J., Fidler, I. J. (2004). Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma. Clin. Cancer Res. 10: 897-908 [Abstract] [Full Text]  
• Peng, B., Dutreix, C., Mehring, G., Hayes, M. J., Ben-Am, M., Seiberling, M., Pokorny, R., Capdeville, R., Lloyd, P. (2004). Absolute Bioavailability of Imatinib (Glivec(R)) Orally versus Intravenous Infusion. J Clin Pharmacol 44: 158-162 [Abstract] [Full Text]